title: Postorthopedic Surgery Joint Replacement Surgery Venous Thromboembolism Prophylaxis.
abstract: Elective total hip or knee arthroplasty places patients at risk for venous thromboembolism (VTE). As our understanding of the pathophysiology of VTE after joint arthroplasty has increased, pharmacologic strategies have been developed to target different aspects of the coagulation cascade. Various approaches have been used as risk reduction strategies. In 2011 and 2014 the Food and Drug Administration approved rivaroxaban and apixaban as new oral antithrombotic agents. Although controversies remain with regard to the ideal VTE pharmacoprophylactic agent, this class of novel oral anticoagulants has been demonstrated to be safe and to be more effective than enoxaparin.
authors.affiliation: Department of Orthopaedic Surgery, Harbor-UCLA Medical Center, 1000 West Carson Street, Box 422, Torrance, CA 90509, USA. Electronic address: lkwong@dhs.lacounty.gov.
authors.forename: Louis M
authors.initials: LM
authors.lastname: Kwong
authors.affiliation: Department of Orthopaedic Surgery, Harbor-UCLA Medical Center, 1000 West Carson Stree, Box 422, Torrance, CA 90509, USA.
authors.forename: Jon A
authors.initials: JA
authors.lastname: Kimball
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D019643:Arthroplasty, Replacement / Q000009:adverse effects*; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects*; D006801:Humans; D011183:Postoperative Complications / Q000097:blood / Q000517:prevention & control*; D013923:Thromboembolism / Q000097:blood / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants
keywords: Apixaban; NOAC; Rivaroxaban; Thrombophrophylaxis; Total hip arthroplasty; Total knee arthroplasty; Venous thromboembolism (VTE)